Mean fluorescence intensity rate is a useful marker in the detection of paroxysmal nocturnal hemoglobinuria clones

Clinical Chemistry and Laboratory Medicine

Volumn 43, Issue 9, 2005, Pages 919-923

  Hevessy, Zsuzsa ^a   Nagy Jr , Béla ^a   Kiss, Flóra ^a   Kiss, Attila ^a   Kappelmayer, János ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

CD14; CD55; CD59; Mean fluorescence intensity; Paroxysmal nocturnal hemoglobinuria

Indexed keywords

CD14 ANTIGEN; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; MEMBRANE PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CELL CLONE; DIAGNOSTIC VALUE; DISEASE SEVERITY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; GRANULOCYTE; HEMOLYSIS; HUMAN; MALE; MONOCYTE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; RELIABILITY;

ANTIGENS, CD14; ANTIGENS, CD55; ANTIGENS, CD59; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; GRANULOCYTES; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MALE; MONOCYTES;

EID: 26844474976     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2005.157     Document Type: Article

References (36)

1. Bessler M, Hillmen P, Longo L, Luzzatto L, Mason PJ. Genomic organization of the X-linked gene (PIG-A) that is mutated in PNH and of a related pseudogene mapped to 12q21. Hum Mol Genet 1994;3:751-62.
2. Miyata T, Takeda J, Iida Y, Yamada N, Inoue N, Takahashi M, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993;259: 1318-20.
3. Bessler M, Mason PJ, Hillmen P, Miyata T, Yamada N, Takeda J, et al. Paroxysmal nocturnal hemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994;13:110-7.
4. Antal-Szalmas P. Evaluation of CD14 in host defence. Eur J Clin Invest 2000;30:167-79.
5. Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 1995;86:3277-86.
6. Araten DJ, Nafa K, Pakdeesuwan K, Luzzato L. Clonal populations of hemopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci 1999; 96:5209-14.
7. Hu R, Mukhina GL, Piantadosi S, Barber JP, Jones RJ, Brodsky RA. PIG-A mutations in normal hematopoiesis. Blood 2005;105:3848-54.
8. Johnson RJ, Hillmen P. Paroxysmal nocturnal hemoglobinuria: nature's gene therapy? Mol Pathol 2002;55: 145-52.
9. Rosse WF. New insights into paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 2001;8:61-7.
10. Chen G, Kirby M, Zeng W, Young NS, Maciejewski JP. Superior growth of glycophosphatidylinositol-anchored protein-deficient progenitor cells in vitro is due to the higher apoptotic rate of progenitors with normal phenotype in vivo. Exp Hematol 2002;30:774-82.
11. Heeney MM, Ormsbee SM, Moody MA, Howard TA, DeCastro CM, Ware RE. Increased expression of antiapoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. Mol Genet Metab 2003;78:291-4.
12. Nakakuma H, Kawaguchi T. Pathogenesis of selective expansion of PNH clones. Int J Hematol 2003;77:121-4.
13. Marsh JC, Elebute MO. Stem cells in paroxysmal nocturnal hemoglobinuria and aplastic anaemia: increasing evidence for overlap of haemopoietic defect. Transfus Med 2003;13:377-86.
14. Nakakuma H. Mechanism of intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). Am J Hematol 1996;53:22-9.
15. Young NS. Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment. Curr Hematol Rep 2005;4:103-9.
16. Sundan A, Ryan L, Brinch L, Espevik T, Waage A. The involvement of CD14 in stimulation of TNF production from peripheral mononuclear cells isolated from PNH patients. Scand J Immunol 1995;41:603-8.
17. Golenbock DT, Bach RR, Lichenstein H, Juan TS, Tadavarthy A, Moldow CF. Soluble CD14 promotes LPS activation of CD14-deficient PNH monocytes and endothelial cells. J Lab Clin Med 1995;125:662-71.
18. Schutt C, Schilling T, Grunwald U, Stelter F, Witt S, Kruger C, et al. Human monocytes lacking the membranebound form of the bacterial lipopolysaccharide (LPS) receptor CD14 can mount an LPS-induced oxidative burst response mediated by a soluble form of CD14. Res Immunol 1995;146:339-50.
19. Ham T. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: study of the mechanism of hemolysis in relation to the acid-base equilibrium. N Engl J Med 1937;915:915-7.
20. Hartmann RC, Jenkins DE. The "sugar-water" test for paroxysmal nocturnal hemoglobinuria. N Engl J Med 1966;275:155-7.
21. Schubert J, Alvarado M, Uciechowski P, Zielinska-Skowronek M, Freund M, Vogt H, et al. Diagnosis of paroxysmal nocturnal hemoglobinuria using immunophenotyping of peripheral blood cells. Br J Haematol 1991;79:487-92.
22. Kwong YL, Lee CP, Chan TK, Chan LC. Flow cytometric measurement of glycosylphosphatidyl-inositol-linked surface proteins on blood cells of patients with paroxysmal nocturnal hemoglobinuria. Am J Clin Pathol 1994; 102:30-5.
23. Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 1996;87:5332-40.
24. Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry (Comm Clin Cytometry) 2000;42:223-33.
25. Piedras J, López-Karpovitch X. Flow cytometric analysis of glycosylphosphatidylinositol-anchored proteins to assess paroxysmal nocturnal hemoglobinuria clone size. Cytometry (Comm Clin Cytometry) 2000;42:234-8.
26. Borowitz MJ. Flow cytometry in PNH. How much is enough? Cytometry (Comm Clin Cytometry) 2000;42: 221-2.
27. Hernandez-Campo PM, Martin-Ayuso M, Almeida J, Lopez A, Orfao A. Comparative analysis of different flow cytometry-based immunophenotypic methods for the analysis of CD59 and CD55 expression on major peripheral blood cell subsets. Cytometry (Comm Clin Cytometry) 2002;50:191-201.
28. Meletis J, Terpos E. Recent insights into the pathophysiology of paroxysmal nocturnal hemoglobinuria. Med Sci Monit 2003;9:161-72.
29. Oelschlaegel U, Besson I, Arnoulet C, Sainty D, Nowak R, Naumann R, et al. A standardized flow cytometric method for screening paroxysmal nocturnal hemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes. Clin Lab Haem 2001;23: 81-90.
30. Hsi ED. Paroxysmal nocturnal hemoglobinuria testing by flow cytometry. Evaluation of the REDQUANT and CELLQUANT kits. Am J Clin Pathol 2000;114:798-806.
31. Kinoshita T, Medof ME, Silber R, Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1985;162: 75-92.
32. Plesner T, Hansen NE, Carlsen K. Estimation of PI-bound proteins on blood cells from PNH patients by quantitative flow cytometry. Br J Haematol 1990;75:585-90.
33. Poncelet P, Besson-Faure I, Lavabre-Bertrand T. Clinical application of quantitative immunophenotyping. In: Stewart CC, Nicholson JK, editors. Immunophenotyping. New York: Wiley-Liss, 2000:117-20.
34. Maciejewski JP, Young NS, Yu M, Anderson SM, Sloand EM. Analysis of the expression of GPI-anchored proteins on platelets from patients with PNH. Thromb Res 1996;83:433-47.
35. Azenishi Y, Ueda E, Machii T, Nishimura J, Hirota T, Shibano M, et al. CD59-deficient blood cells and PIG-A gene abnormalities in Japanese patients with aplastic anemia. Br J Haematol 1999;104:523-9.
36. Rawstron AC, Rollinson SJ, Richards S, Short MA, English A, Morgan GJ, et al. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol 1999;107: 148-53.